– Advicenne signs its first Sibnayal® distribution agreement outside Europe with Taiba Healthcare, one of the rare disease leading pharmaceutical company in Middle East– Advicenne will receive a transfer price and royalties for an amount markedly higher than 50% of future sales of Sibnayal®
The partnership with Taiba is the first Advicenne has signed for Sibnayal® outside of Europe. Under the terms of the agreement, Taiba has exclusive marketing rights to Sibnayal® in its indication of the territories defined in the contract. In return, Advicenne will receive the proceeds from the sale of Sibnayal® in the form of a transfer price and royalties for a combined amount significantly greater than 50% of future sales. Taiba is currently working on an early access program for Sibnayal® in the contract territories. Taiba and Advicenne will be responsible for the registration of products locally based on the registration dossier file that enabled the marketing authorization in Europe and the United Kingdom.
Following recent collaboration agreements with TwinPharma, ExCEEd Orphan and Frost Pharma in Europe, Advicenne is continuing to make its drug Sibnayal® as widely available as possible.
Didier Laurens, Chief Executive Officer of Advicenne, commented: “We are delighted with the signing of this agreement with Taiba Healthcare, regional leader in the marketing of products for rare diseases in the Gulf countries, where prevalence of distal Renal Tubular Acidosis is amongst the higher worldwide. This is the fourth agreement in a few months and the first one outside Europe, proof of our willingness to make Sibnayal® available to the largest number of patients and to meet a medical need that is still poorly covered.”
Saif Al Hasani, Chief Executive Officer of Taiba Healthcare stated: “We are proud to be partnering with Advicenne for the delivery of Sibnayal® to patients and improve the lives of those suffering from dRTA. We look forward to working with them and to be continuing to expand our product portfolio in areas of high unmet need.”
Sources:
